Loading…
Reported covered position: Senator Christopher Bond - Legislative Correspondent Representative Jo Ann Emerson - Administration Assistant Representative Charles Bass - SeniorPolicy Advisor
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Protecting Consumer Access to Generic Drugs Act of 2019
Client: GLENMARK PHARMACEUTICALS USA · Firm: GLENMARK PHARMACEUTICALS USA
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
Protecting Consumer Access to Generic Drugs Act of 2019
Client: GLENMARK PHARMACEUTICALS USA · Firm: GLENMARK PHARMACEUTICALS USA
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
GLENMARK PHARMACEUTICALS USA via GLENMARK PHARMACEUTICALS USA
2022 · third_quarter · 3T
Generic drug exclusivity; BLOCKING Act; prescription drug manufacturing.
Medicaid Generics Penalty
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
BLOCKING Act of 2019
Client: GLENMARK PHARMACEUTICALS USA · Firm: GLENMARK PHARMACEUTICALS USA
HR 938, BLOCKING Act, issues related to pharmaceutical manufacturing supply chain
BLOCKING Act of 2019
Client: GLENMARK PHARMACEUTICALS USA · Firm: GLENMARK PHARMACEUTICALS USA
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
BLOCKING Act of 2019
Client: GLENMARK PHARMACEUTICALS USA · Firm: GLENMARK PHARMACEUTICALS USA
HR 938, BLOCKING Act, issues related to pharmaceutical manufacturing supply chain
BLOCKING Act of 2019
Client: GLENMARK PHARMACEUTICALS USA · Firm: GLENMARK PHARMACEUTICALS USA
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: GLENMARK PHARMACEUTICALS USA · Firm: GLENMARK PHARMACEUTICALS USA
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: GLENMARK PHARMACEUTICALS USA · Firm: GLENMARK PHARMACEUTICALS USA
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
Protecting Consumer Access to Generic Drugs Act of 2019
Client: GLENMARK PHARMACEUTICALS USA · Firm: GLENMARK PHARMACEUTICALS USA
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
Protecting Consumer Access to Generic Drugs Act of 2019
Client: GLENMARK PHARMACEUTICALS USA · Firm: GLENMARK PHARMACEUTICALS USA
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
Protecting Consumer Access to Generic Drugs Act of 2019
Client: GLENMARK PHARMACEUTICALS USA · Firm: GLENMARK PHARMACEUTICALS USA
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
Protecting Consumer Access to Generic Drugs Act of 2019
Client: GLENMARK PHARMACEUTICALS USA · Firm: GLENMARK PHARMACEUTICALS USA
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
BLOCKING Act of 2019
Client: GLENMARK PHARMACEUTICALS USA · Firm: GLENMARK PHARMACEUTICALS USA
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
BLOCKING Act of 2019
Client: GLENMARK PHARMACEUTICALS USA · Firm: GLENMARK PHARMACEUTICALS USA
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
BLOCKING Act of 2019
Client: GLENMARK PHARMACEUTICALS USA · Firm: GLENMARK PHARMACEUTICALS USA
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
BLOCKING Act of 2019
Client: GLENMARK PHARMACEUTICALS USA · Firm: GLENMARK PHARMACEUTICALS USA
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: GLENMARK PHARMACEUTICALS USA · Firm: GLENMARK PHARMACEUTICALS USA
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: GLENMARK PHARMACEUTICALS USA · Firm: GLENMARK PHARMACEUTICALS USA
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: GLENMARK PHARMACEUTICALS USA · Firm: GLENMARK PHARMACEUTICALS USA
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: GLENMARK PHARMACEUTICALS USA · Firm: GLENMARK PHARMACEUTICALS USA
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
CREATES Act of 2017
Client: GLENMARK PHARMACEUTICALS USA · Firm: GLENMARK PHARMACEUTICALS USA
FDA User Fees, HR 749, Lower Drug Costs Through Competition Act, CREATES Act (HR 2212 and S 974)
CREATES Act of 2017
Client: GLENMARK PHARMACEUTICALS USA · Firm: GLENMARK PHARMACEUTICALS USA
FDA User Fees, HR 749, Lower Drug Costs Through Competition Act, CREATES Act (HR 2212 and S 974), Generic CPI penalty.
Lower Drug Costs through Competition Act
Client: GLENMARK PHARMACEUTICALS USA · Firm: GLENMARK PHARMACEUTICALS USA
FDA User Fees, HR 749
Lower Drug Costs through Competition Act
Client: GLENMARK PHARMACEUTICALS USA · Firm: GLENMARK PHARMACEUTICALS USA
FDA User Fees, HR 749, Lower Drug Costs Through Competition Act, CREATES Act (HR 2212 and S 974), Generic CPI penalty.
Lower Drug Costs through Competition Act
Client: GLENMARK PHARMACEUTICALS USA · Firm: GLENMARK PHARMACEUTICALS USA
FDA User Fees, HR 749, Lower Drug Costs Through Competition Act, CREATES Act (HR 2212 and S 974)
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: GLENMARK PHARMACEUTICALS USA · Firm: GLENMARK PHARMACEUTICALS USA
FDA User Fees, HR 749, Lower Drug Costs Through Competition Act, CREATES Act (HR 2212 and S 974)
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: GLENMARK PHARMACEUTICALS USA · Firm: GLENMARK PHARMACEUTICALS USA
FDA User Fees, HR 749, Lower Drug Costs Through Competition Act, CREATES Act (HR 2212 and S 974), Generic CPI penalty.
2022 · second_quarter · Q2
Generic drug exclusivity; BLOCKING Act; prescription drug manufacturing.
Medicaid Generics Penalty
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLENMARK PHARMACEUTICALS USA via GLENMARK PHARMACEUTICALS USA
2022 · first_quarter · Q1
Medicaid Generics Penalty
Generic drug exclusivity; BLOCKING Act; prescription drug manufacturing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLENMARK PHARMACEUTICALS USA via GLENMARK PHARMACEUTICALS USA
2021 · fourth_quarter · Q4
Medicaid generics penalty
Generic drug exclusivity; BLOCKING Act; prescription drug manufacturing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLENMARK PHARMACEUTICALS USA via GLENMARK PHARMACEUTICALS USA
2021 · third_quarter · Q3
Generic drug exclusivity; BLOCKING Act; prescription drug manufacturing.
Medicaid generics penalty
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLENMARK PHARMACEUTICALS USA via GLENMARK PHARMACEUTICALS USA
2021 · second_quarter · Q2
Generic drug exclusivity; BLOCKING Act; prescription drug manufacturing.
Medicaid generics penalty
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLENMARK PHARMACEUTICALS USA via GLENMARK PHARMACEUTICALS USA
2021 · first_quarter · Q1
Generic drug exclusivity; BLOCKING Act; prescription drug manufacturing.
Medicaid generics penalty
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLENMARK PHARMACEUTICALS USA via GLENMARK PHARMACEUTICALS USA
2020 · fourth_quarter · Q4
HR 938, BLOCKING Act, issues related to pharmaceutical manufacturing supply chain
Medicaid Generics Penalty
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLENMARK PHARMACEUTICALS USA via GLENMARK PHARMACEUTICALS USA
2020 · third_quarter · Q3
Medicaid Generics Penalty
HR 938, BLOCKING Act, issues related to pharmaceutical manufacturing supply chain
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLENMARK PHARMACEUTICALS USA via GLENMARK PHARMACEUTICALS USA
2020 · second_quarter · Q2
Medicaid Generics Penalty
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLENMARK PHARMACEUTICALS USA via GLENMARK PHARMACEUTICALS USA
2020 · first_quarter · Q1
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
Medicaid Generics Penalty
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLENMARK PHARMACEUTICALS USA via GLENMARK PHARMACEUTICALS USA
2019 · fourth_quarter · Q4
Medicaid Generics Penalty
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLENMARK PHARMACEUTICALS USA via GLENMARK PHARMACEUTICALS USA
2019 · third_quarter · Q3
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
Medicaid Generics Penalty
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLENMARK PHARMACEUTICALS USA via GLENMARK PHARMACEUTICALS USA
2019 · second_quarter · Q2
Medicaid Generics Penalty
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLENMARK PHARMACEUTICALS USA via GLENMARK PHARMACEUTICALS USA
2019 · first_quarter · Q1
Medicaid Generics Penalty
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLENMARK PHARMACEUTICALS USA via GLENMARK PHARMACEUTICALS USA
2018 · fourth_quarter · Q4
Prescription drug costs
Medicaid Generics Penalty
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLENMARK PHARMACEUTICALS USA via GLENMARK PHARMACEUTICALS USA
2018 · third_quarter · Q3
Medicaid Generics Penalty
Prescription drug costs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLENMARK PHARMACEUTICALS USA via GLENMARK PHARMACEUTICALS USA
2018 · second_quarter · Q2
Prescription drug costs
Medicaid Generics Penalty
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLENMARK PHARMACEUTICALS USA via GLENMARK PHARMACEUTICALS USA
2018 · first_quarter · Q1
Prescription drug costs
Medicaid Generics Penalty, Medicaid Rebates
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLENMARK PHARMACEUTICALS USA via GLENMARK PHARMACEUTICALS USA
2017 · fourth_quarter · 4A
Generic CPI penalty.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLENMARK PHARMACEUTICALS USA via GLENMARK PHARMACEUTICALS USA
2017 · third_quarter · Q3
FDA User Fees, HR 749, Lower Drug Costs Through Competition Act, CREATES Act (HR 2212 and S 974), Generic CPI penalty.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLENMARK PHARMACEUTICALS USA via GLENMARK PHARMACEUTICALS USA
2017 · second_quarter · Q2
FDA User Fees, HR 749, Lower Drug Costs Through Competition Act, CREATES Act (HR 2212 and S 974)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLENMARK PHARMACEUTICALS USA via GLENMARK PHARMACEUTICALS USA
2017 · first_quarter · 1A
FDA User Fees, HR 749
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLENMARK PHARMACEUTICALS USA via GLENMARK PHARMACEUTICALS USA
2017 · first_quarter · RA
FDA User Fees, Tax Reform, Pharmaceutical Pricing
FDA User Fees, Tax Reform, Pharmaceutical Pricing
FDA User Fees, Tax Reform, Pharmaceutical Pricing
GLENMARK PHARMACEUTICALS USA via GLENMARK PHARMACEUTICALS USA
2017 · first_quarter · RR
FDA User Fee Legislation, Tax Reform
FDA User Fee Legislation, Tax Reform
FDA User Fee Legislation, Tax Reform